Itay24

basketball and snowboarding that's all I need

[Alpha Tau Medical @AlphaTauMedical]

Fox Business said it right: ASCO 2026 is the Super Bowl of oncology and Alpha Tau is the rising star in the game that is becoming impossible to ignore.

[Alpha Tau Insight @AlphaTauInsight]

$DRTS CFO ahead of the several cancer trial readouts expected this year: “Last trial we read out we saw 100% complete response rate, every tumor disappeared of course, and we saw no serious side effects”

[Finn Stockinger @FinnStockinger]

Alpha Tau $DRTS: The Isotope Sniper vs. Market Noise. Why March 2026 is the Inflection Point.

While speculative capital is currently bleeding out of ImmunityBio ($IBRX), which hit a regulatory wall after aggressive marketing triggered FDA warning letters (down 21% this week) - smart money is quietly rotating into Alpha Tau Medical ($DRTS).

This isn't just "another biotech."

This is a company that has cleared the world's toughest regulatory hurdle, yet its valuation still fails to reflect the incoming wave of commercialization.

1⃣The Tech: Why $DRTS Wins Over Tradition

Radiation therapy has historically been "carpet bombing" - effective, but devastating to the surrounding environment.

Alpha DaRT technology introduces sniper-like precision. It utilizes alpha-particle emitters (Radium-224), which possess massive kinetic energy to shred cancer DNA, but a range of less than 0.1 mm.

➡️The Core Advantage:

We can "burn out" a tumor from the inside without touching healthy tissue just a millimeter away.

More importantly for combo-therapy strategies: Alpha DaRT does not destroy the immune system (no lymphopenia), as confirmed by recent pancreatic cancer data (81% disease control rate).

This makes it the perfect partner for immunotherapies.

2⃣Japan and the Logistical "Moat"

The Japanese PMDA approval on February 24, 2026, was the ultimate De-risking Event.

Japan has the most stringent safety standards globally; their "yes" is a quality certificate for the rest of the world.

However, the real value lies in the logistics.

Radium-224 has a half-life of only 3.6 days.

Alpha Tau’s nearly completed facility in New Hampshire isn't just an investment; it’s a barrier to entry.

Competitors cannot "copy" this model overnight. In radiopharmaceuticals, he who owns the nuclear permits and the factory closest to the patient dictates the terms.

3⃣The Cold Assessment: Risks and the "Bear Case"

No research is 10/10 without addressing the threats. Investors must consider:

➡️Dilution Risk:

While the company has cash through 2027, biotechs often conduct a public offering following major news (e.g., the Q2 Glioblastoma data) to fund global roll-out. Expect volatility.

➡️Competition:

Actinium Pharmaceuticals ($ATNM) and RayzeBio (Novartis) are breathing down their necks. While DRTS has unique diffusion tech, the fight for hospital budgets will be brutal.

➡️ReSTART Trial: If the pivotal U.S. trial shows even marginally weaker results than the Japanese data, the market will likely overreact with a panic sell-off.

3⃣The $IBRX Lesson: Fundamentals > Hype

The ImmunityBio case proves that aggressive marketing without flawless FDA documentation is a recipe for disaster.

$DRTS is following the "Device" (PMA) pathway rather than the "Drug" (BLA) pathway, which historically offers a faster route to full U.S. commercialization and less bureaucratic friction regarding manufacturing changes.

4⃣Investment Strategy

➡️Entry Point:

The current consolidation in the $6.80 - $7.15 range looks like institutional accumulation.

➡️Binary Catalyst:

Glioblastoma (GBM) data in Q2 2026.

Success in brain cancer is an immediate re-rating event and makes the company a prime M&A target for giants like AstraZeneca or Novartis.

➡️Stop Loss:

A technical exit below $6.10, which would negate the institutional support thesis.

⬇️Verdict:

You are buying sniper technology at the price of a slingshot.

$DRTS is currently the most compelling risk/reward profile in the MedTech sector.

You are getting technology already validated by Japan at a pre-hype U.S. price.

🗨️Is $DRTS the sleeper MedTech play of 2026, or is the biotech sector too volatile right now?

Drop a Like ❤️ if you’re watching this space, and let me know your top pick for Q2 below! 👇

[Alpha Tau Insight @AlphaTauInsight]

“Q2 catalysts success could drive 2-3x returns”

Dr. Elena Voss, Senior Biotech Equity Analyst, believes $DRTS is a “high-reward biotech with tangible de-risking milestones ahead.”

[Alpha Tau Insight @AlphaTauInsight]

NEW: Alpha Tau Medical (NASDAQ: $DRTS) March 2026 Investor Presentation

Highlights:
- Upcoming catalysts
- Massive potential TAM
- FDA relationship
- ⁠Keytruda combination trial
- ⁠Manufacturing and Finances

[Alpha Tau Insight @AlphaTauInsight]

“I’m cancer free thanks to $DRTS."

With hundreds of successfully treated patients worldwide, this FDA Breakthrough Device is a smarter way to treat cancer. Now approved in Japan with many upcoming catalysts.

[Alpha Tau Insight @AlphaTauInsight]

״בעזרת הטיפול הזה, קיבלתי את איכות החיים המלאה שהייתה לי לפני שחליתי, מלאה אני מתכוון 100%״

לוחם השייטת לשעבר שנרפא מסרטן בזכות הטיפול של של חברת אלפא תאו $DRTS, מספר על ההחלטה ששינתה את חייו.

[Alpha Tau Insight @AlphaTauInsight]

Citi and H.C. Wainwright raise price targets on $DRTS to $9 and $12.

Analysts say Japan’s approval validates the platform, de-risks U.S. progress, and is leading to partnership opportunities.

Upcoming catalysts include Phase 3 completion, Pancreatic and GBM trials, the Keytruda combination study, and more.

[Alpha Tau Insight @AlphaTauInsight]

Citi raises $DRTS price target to 9$.

“The firm believes the company’s radiopharma platform is being underappreciated at current share levels.

Alpha Tau’s broader-than-expected Japan approval in head and neck cancer is leading to partnership opportunities.”

[Alpha Tau Insight @AlphaTauInsight]

JUST IN: $DRTS to share results from first GBM patients.

Alpha Tau will hold an initial safety readout this coming quarter for the first three patients treated, followed by completion of patient recruitment for their FDA Recurrent Glioblastoma trial.

[Alpha Tau Insight @AlphaTauInsight]

Connie, 71, after being treated by $DRTS: “I haven’t had any side effects. The cancer was not there, the Alpha DaRT seeds killed the cancer cells. That to me was just a miracle”

[Alpha Tau Insight @AlphaTauInsight]

A trial combining Alpha DaRT by $DRTS and Keytruda (the #1 selling drug in the world) by Merck has shown promising results!

Alpha DaRT has significantly improved the results (19%->100% response rate) showing potential systemic and metastatic effects beyond the local treatment.

[Alpha Tau Insight @AlphaTauInsight]

Could $DRTS be the first ever cancer vaccine?

Doctors discovered the Alpha DaRT treatment awakens the immune system and teaches it to fight cancer elsewhere in the body.

Now it is being tested with Keytruda, the #1 selling drug in the world, with very promising results.

[Alpha Tau Insight @AlphaTauInsight]

$DRTS's clinical, regulatory and commercial achievements for their revolutionary cancer treatment:

- FDA Breakthrough Device Designation
- FDA TAP program inclusion
- FDA MDSAP certification
- PMDA approval in Japan
- FDA PHASE 3 completion in Q1 2026
- FDA IDE’s for five cancers and counting
- FDA approval for commercial factory in the US, with other factories built and more in planing
- 100% tumor response rate in early FDA trials
- Effective against all tumor types, including the most high unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc…
- Activates immune system
- ⁠55+ clinical sites worldwide (including USA, UK, Canada, France, Germany, Russia, Italy, Japan…)
- Patents, IP and more…

[Alpha Tau Insight @AlphaTauInsight]

After securing the PMDA marketing approval, these are the upcoming catalysts for $DRTS:

- Completing Phase 3 cSCC in Q1
- ⁠Completing Pancreas trial in H1
- ⁠Completing GBM trial
All three will be sharing results this year.
- Combination trial with Keytruda (the #1 selling drug in the world)
- Strategic Partnerships
- ⁠Commercialization
- ⁠Manufacturing
- ⁠New US trials (Prostste, H&N)
- ⁠55+ Clinical sites worldwide treating many different indications including Lungs, Breast, Liver and all
- ⁠Conferences and Presentations
- ⁠And more!

[Alpha Tau Insight @AlphaTauInsight]

🚨WATCH: $DRTS CEO after the stock surges on the Japanese approval news: We’re not looking to raise capital, we’re finishing FDA Phase 3 trial this quarter, Pancreas trial in H1 this year, GBM trial also this year, starting new trials and are forming strategic partnerships.

[Alpha Tau Insight @AlphaTauInsight]

🚨מנכ״ל $DRTS בעקבות עליית מחיר המניה לאחר האישור המסחרי ביפן: אנחנו עוד לא מחפשים לגייס כסף, אנחנו מסיימים את Phase 3 של הFDA ברבעון הזה, את הניסוי בסרטן הלבלב במחצית הראשונה של השנה, את הניסוי בסרטן המוח גם השנה, מתחילים עוד ניסויים ומתבשלים שת״פים אסטרטגיים עם חברות אחרות.

[Block_86 @Judhoff]

$DRTS approved in Japan!

[Alpha Tau Medical @AlphaTauMedical]

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer

https://t.co/rEgORYZIRj

[daiying.zhang @zdying2024]

News:
$DRTS [Clinical/Drug]
Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer
#pennystocks #marketnews #newsalert #kairalert